Wells A. Messersmith, MD

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, and professor of medicine, at the University of Colorado School of Medicine, discusses the need for biomarkers to distinguish between VEGF inhibitors in colorectal cancer (CRC).

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses the rise of molecular testing in metastatic colorectal cancer (mCRC).

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).